LncRNA PVT-1 promotes osteosarcoma cancer stem-like properties through direct interaction with TRIM28 and TSC2 ubiquitination

Susan V. Tsang,Nino Rainusso,Meng Liu,Motonari Nomura,Tajhal D. Patel,Kengo Nakahata,Ha Ram Kim,Shixia Huang,Kimal Rajapakshe,Cristian Coarfa,Tsz-Kwong Man,Pulivarthi H. Rao,Jason T. Yustein

DOI: https://doi.org/10.1038/s41388-022-02538-w

IF: 8.756

2022-11-09

Oncogene

Abstract:Osteosarcoma, the most common pediatric bone tumor, is an aggressive heterogeneous malignancy defined by complex chromosomal aberrations. Overall survival rates remain at ~70%, but patients with chemoresistant or metastatic disease have extremely poor outcomes of <30%. A subgroup of tumors harbor amplification of chromosome 8q24.2 and increased expression of the oncogenic long noncoding RNA (lncRNA) Plasmacytoma Variant Translocation-1 ( PVT-1) , which is associated with an extremely poor clinical prognosis. This study demonstrates that PVT-1 is critical for osteosarcoma tumor-initiation potential. Chromatin Hybridization by RNA Purification analysis identified Tripartite-Motif Containing Family 28 (TRIM28) as a novel PVT-1 binding partner. Mechanistically, co-immunoprecipitation studies showed the PVT-1 /TRIM28 complex binds and increases SUMOylation of phosphatidylinositol 3-kinase catalytic subunit type 3 (Vps34), which leads to enhanced ubiquitination and degradation of tumor suppressor complex 2 (TSC2), thus contributing to increased self-renewal and stem cell phenotypes. Furthermore, we identified that osteosarcoma cells with increased PVT-1 have enhanced sensitivity to the SUMOylation inhibitor, TAK-981. Altogether, this study elucidated a role for PVT-1 in the enhancement of cancer stem-like behaviors, including migration and invasion, in osteosarcoma, and identified the novel PVT-1 /TRIM28 axis signaling cascade as a potential therapeutic target for osteosarcoma treatment.

oncology,genetics & heredity,biochemistry & molecular biology,cell biology